

# The continuous and semi-continuous bioprocessing market by Roots Analysis


Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings.

LONDON, ENGLAND, UNITED KINGDOM, September 8, 2021 /EINPresswire.com/ -- The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification

[Roots Analysis](#) has announced the addition of “[Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030](#)” report to its list of offerings.

Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.

To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this <https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html>



## Key Market Insights

Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics

Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.

Over 65% of the installed continuous upstream manufacturing capacity belongs to established players  
More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.


Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost

By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.

By 2030, the opportunity within the continuous and [semi-continuous bioprocessing market](#) is likely to be over USD 500 million

Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.

To request a sample copy / brochure of this report, please visit this



<https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html>

## Key Questions Answered

- Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?
- Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?
- In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
- What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
- What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
- How is the current and future market opportunity likely to be distributed across key market segments?

The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:

- Type of Manufacturer
  - Innovator / Drug Developer
  - Contract Service Provider

## □ Company Size

- Large
- Mid-sized
- Small

## □ Scale of Operation

- Preclinical / Clinical
- Commercial

## □ Stage of Bioprocess

- Upstream Bioprocessing
- Downstream Bioprocessing

## □ Geographical Regions

- North America
- Europe
- Asia-Pacific
- MENA
- Latin America and Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:

- John Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)
- Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
- Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

- AGC Biologics
- Biogen
- Bristol-Myers Squibb
- Enzene Biosciences
- EUJIFLM Diosynth Biotechnologies
- Merck KGaA
- Novasep
- Sanofi Genzyme
- CB Pharma
- WuXi Biologics

For additional details, please visit

<https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html> or email [sales@rootsanalysis.com](mailto:sales@rootsanalysis.com)

You may also be interested in the following titles:

1. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
2. Lipid Contract Manufacturing Market: Industry Trends and Global Forecasts, 2021-2030
3. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030

Contact:

Ben Johnson  
+1 (415) 800 3415  
+44 (122) 391 1091  
ben.johnson@rootsanalysis.com

Gaurav Chaudhary  
Roots Analysis  
+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/550839855>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.